Collaboration with Lupvindol Biosciences will initially target companion-animal oncology and chronic pain management

Splash retains ownership of resulting data, intellectual property and commercialization rights

FORT LAUDERDALE, Fla., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE:SBEV) ("Splash" or the "Company") today announced that it has entered into a strategic development and collaboration agreement with Lupvindol Biosciences Ltd. to advance CannEpil® as a potential FDA-regulated veterinary pharmaceutical product for companion-animal oncology and chronic pain management.

The milestone-driven program is designed to advance CannEpil through the U.S. Food and Drug Administration’s Center for Veterinary Medicine, beginning with the Investigational New Animal Drug ("INAD") process and progressing toward potential conditional approval pursuant to Section 571 of the Federal Food, Drug, and Cosmetic Act ("Conditional Approval"). Canine applications are expected to represent the initial development focus.

Lupvindol will lead the scientific, product-development and FDA regulatory activities, including preparation of the INAD submission, development of an FDA-acceptable product development plan, study design and oversight, regulatory correspondence and preparation of a potential Conditional Approval submission.

Splash will provide milestone-based funding and lead commercialization strategy, strategic partnering and capital-markets activities. Importantly, Splash will own the medical technology, study data, regulatory submissions and foreground intellectual property generated through the collaboration and will retain control over future licensing and commercialization decisions.